Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Stock Report

Market Cap: CN¥19.4b

Tianjin Pharmaceutical Da Ren Tang Group Future Growth

Future criteria checks 4/6

Tianjin Pharmaceutical Da Ren Tang Group is forecast to grow earnings and revenue by 20.8% and 10% per annum respectively. EPS is expected to grow by 21% per annum. Return on equity is forecast to be 21.7% in 3 years.

Key information

20.8%

Earnings growth rate

21.0%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate10.0%
Future return on equity21.7%
Analyst coverage

Low

Last updated16 Aug 2024

Recent future growth updates

Recent updates

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Earnings and Revenue Growth Forecasts

SHSE:600329 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610,4931,610N/A1,2283
12/31/20259,5931,362N/A9913
12/31/20248,7901,150N/A1,2193
6/30/20248,0999221,0081,121N/A
12/31/20238,222987548688N/A
9/30/20238,479991511632N/A
6/30/20238,5631,116591711N/A
3/31/20238,5141,063679785N/A
12/31/20228,249862569677N/A
9/30/20227,118837188302N/A
6/30/20227,042775433572N/A
3/31/20226,970756656818N/A
12/31/20216,908769695852N/A
9/30/20216,999846770937N/A
6/30/20216,954801570737N/A
3/31/20216,775705472646N/A
12/31/20206,604662482671N/A
9/30/20206,773657425633N/A
6/30/20206,751602414643N/A
3/31/20206,896605291519N/A
12/31/20196,994626290495N/A
9/30/20196,847606125297N/A
6/30/20196,780595111294N/A
3/31/20196,497578109287N/A
12/31/20186,359562174350N/A
9/30/20186,084517154332N/A
6/30/20185,81451235167N/A
3/31/20185,823516N/A170N/A
12/31/20175,689476N/A-4N/A
9/30/20175,747433N/A219N/A
6/30/20175,952443N/A315N/A
3/31/20176,081438N/A304N/A
12/31/20166,243424N/A418N/A
9/30/20166,845467N/A378N/A
6/30/20166,997471N/A280N/A
3/31/20167,104452N/A326N/A
12/31/20157,081451N/A361N/A
9/30/20157,026436N/A208N/A
6/30/20157,114398N/A338N/A
3/31/20157,156375N/A424N/A
12/31/20147,087358N/A287N/A
9/30/20146,621372N/A408N/A
6/30/20146,267361N/A261N/A
3/31/20146,113336N/A158N/A
12/31/20136,010352N/A213N/A
9/30/20135,749307N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600329's forecast earnings growth (20.8% per year) is above the savings rate (2.9%).

Earnings vs Market: 600329's earnings (20.8% per year) are forecast to grow faster than the CN market (17% per year).

High Growth Earnings: 600329's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600329's revenue (10% per year) is forecast to grow slower than the CN market (10.5% per year).

High Growth Revenue: 600329's revenue (10% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600329's Return on Equity is forecast to be high in 3 years time (21.7%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y